{"id":6636,"date":"2024-06-11T13:14:28","date_gmt":"2024-06-11T13:14:28","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=6636"},"modified":"2024-06-28T09:00:42","modified_gmt":"2024-06-28T09:00:42","slug":"european-drug-report-2024-trends-and-developments","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/european-drug-report-2024-trends-and-developments\/","title":{"rendered":"European Drug Report 2024: Trends and Developments"},"content":{"rendered":"\n<p>How is Europe&#8217;s opioid market evolving? What substances are causing the most concern today? How are countries responding to cannabis use?&nbsp;This is among the issues highlighted today by the EU Drugs Agency (EMCDDA) as it launches its <a href=\"https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024_en\"><strong>European Drug Report 2024: Trends and Developments<\/strong><\/a> in an online press conference.<\/p>\n\n\n\n<p>Based on data from <strong>29 countries<\/strong> <strong>(EU 27, T\u00fcrkiye <\/strong>and<strong> Norway)<\/strong>, the online report delivers the latest overview of the drug situation in Europe, exploring long-term trends and emerging threats. The comprehensive analysis covers drug use and supply as well as drug-related harms and responses to them.<\/p>\n\n\n\n<p>Over <strong>100 interactive graphics<\/strong> complement the analysis, while dedicated<strong> interactive<\/strong> <strong>dashboards <\/strong>allow&nbsp;users to visualise data and trends at European and national level. Data journalists and researchers will be able to access the <strong><a href=\"https:\/\/www.emcdda.europa.eu\/data\/source-data\/edr\/2024\/complete_en\">source data<\/a><\/strong> for easier sharing and re-use. The resource is designed to be read across a range of devices (PCs, mobiles, tablets).&nbsp;<\/p>\n\n\n\n<p>Accompanying the report is the <strong><a href=\"https:\/\/www.emcdda.europa.eu\/data\/stats2024_en\">2024 Statistical Bulletin<\/a><\/strong> containing national datasets.<\/p>\n\n\n\n<p style=\"padding-top:15px\"><strong><a href=\"https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024_en\">Digital format of European Drug Report 2024: Trends and Developments<\/a><\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024\/drug-situation-in-europe-up-to-2024_en\">Europe\u2019s drug situation in 2024 \u2013 key developments<\/a><\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.emcdda.europa.eu\/news\/2024\/7\/european-drug-report-2024-highlights_en\">News release<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>How is Europe&#8217;s opioid market evolving? What substances are causing the most concern today? How are countries responding to cannabis use?&nbsp;This is among the issues highlighted today by the EU Drugs Agency (EMCDDA) as it launches its European Drug Report 2024: Trends and Developments in an online press conference. Based on data from 29 countries [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6635,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6636"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=6636"}],"version-history":[{"count":3,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6636\/revisions"}],"predecessor-version":[{"id":6698,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6636\/revisions\/6698"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media\/6635"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=6636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=6636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=6636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}